Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients

被引:16
|
作者
Fernandez-Diaz, Carlos [1 ]
Atienza-Mateo, Belen [1 ]
Castaneda, Santos [2 ]
Melero-Gonzalez, Rafael B. [3 ]
Ortiz-SanJuan, Francisco [4 ]
Loricera, Javier [1 ]
Casafont-Sole, Ivette [5 ]
Rodriguez-Garcia, Sebastian [6 ]
Aguilera-Cros, Clara [7 ]
Villa-Blanco, Ignacio [8 ]
Raya-Alvarez, Enrique [9 ]
Ojeda-Garcia, Clara [10 ]
Bonilla, Gema [11 ]
Lopez-Robles, Alejandra [12 ]
Arboleya, Luis [13 ]
Narvaez, Javier [14 ]
Cervantes, Evelin [15 ]
Maiz, Olga [16 ]
Alvarez-Rivas, Maria N. [17 ]
Cabezas, Ivan [18 ]
Salgado, Eva [19 ]
Hidalgo-Calleja, Cristina [20 ]
Fernandez, Sabela [21 ]
Fernandez, Jesus C. [22 ]
Ferraz-Amaro, Ivan [23 ]
Gonzalez-Gay, Miguel A. [1 ]
Blanco, Ricardo [1 ]
机构
[1] Univ Cantabria, Rheumatol, HU Marques de Valdecilla, IDIVAL, Santander, Spain
[2] UAM, Rheumatol, HU La Princesa, IIS Princesa,Catedra UAM Roche EPID Future, Madrid, Spain
[3] CHU Vigo, Rheumatol, Vigo, Spain
[4] HU La Fe, Rheumatol, Valencia, Spain
[5] HU Germans Trias & Pujol, Rheumatol, Madrid, Spain
[6] HU Clin, Rheumatol, Barcelona, Spain
[7] HU Virgen del Rocio, Rheumatol, Seville, Spain
[8] H Torrelavega, Rheumatol, Cantabria, Spain
[9] HU San Cecilio, Rheumatol, Granada, Spain
[10] HU Virgen Macarena, Rheumatol, Seville, Spain
[11] HU La Paz, Rheumatol, Madrid, Spain
[12] HU Leon, Rheumatol, Leon, Spain
[13] HU Cent Asturias, Rheumatol, Asturias, Spain
[14] HU Bellvitge, Rheumatol, Barcelona, Spain
[15] HU Santiago, Rheumatol, Santiago De Compostela, A Coruna, Spain
[16] HU Donostia, Rheumatol, Donosti, Spain
[17] HU Luca Augusti, Rheumatol, Lugo, Spain
[18] HU Rio Hortega, Rheumatol, Valladolid, Spain
[19] CHU Ourense, Rheumatol, Orense, Spain
[20] HU Salamanca, Rheumatol, Salamanca, Spain
[21] HU Cabuenes, Rheumatol, Asturias, Spain
[22] CHU A Coruna, Rheumatol, La Coruna, Spain
[23] HU Canarias, Rheumatol, Tenerife, Spain
关键词
rheumatoid arthritis; interstitial lung disease; abatacept; methotrexate; conventional disease-modifying antirheumatic drugs; high-resolution computed tomography; comorbidity; METHOTREXATE; MORTALITY; CLASSIFICATION; PNEUMONITIS; CRITERIA; RISK; DRUG;
D O I
10.1093/rheumatology/keab317
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the efficacy and safety of abatacept (ABA) in monotherapy (ABA(MONO)) vs combined ABA [ABA plus MTX (ABA(MTX)) or ABA plus non-MTX conventional synthetic DMARDs (csDMARDs) (ABA(NON-MTX))] in RA patients with interstitial lung disease (ILD) (RA-ILD). Methods This was a restrospective multicentre study of RA-ILD Caucasian patients treated with ABA. We analysed in the three groups (ABA(MONO), ABA(MTX), ABA(NON-MTX)) the following outcome variables: (i) dyspnoea; (ii) forced vital capacity (FVC) and diffusion capacity of the lung for the carbon monoxide (DLCO); (iii) chest high-resolution CT (HRCT); (iv) DAS28-ESR; (v) CS-sparing effect; and (vi) ABA retention and side-effects. Differences between basal and final follow-up were evaluated. Multivariable linear regression was used to assess the differences between the three groups. Results We studied 263 RA-ILD patients (mean +/- s.d. age 64.6 +/- 10 years) [ABA(MONO) (n = 111), ABA(MTX) (n = 46) and ABA(NON-MTX) (n = 106)]. At baseline, ABA(MONO) patients were older (67 +/- 10 years) and took higher prednisone dose [10 (interquartile range 5-15) mg/day]. At that time, there were no statistically significant differences in sex, seropositivity, ILD patterns, FVC and DLCO, or disease duration. Following treatment, in all groups, most patients experienced stabilization or improvement in FVC, DLCO, dyspnoea and chest HRCT as well as improvement in DAS28-ESR. A statistically significant difference between basal and final follow-up was only found in CS-sparing effect in the group on combined ABA (ABA(MTX) or ABA(NON-MTX)). However, in the multivariable analysis, there were no differences in any outcome variables between the three groups. Conclusion In Caucasian individuals with RA-ILD, ABA in monotherapy or combined with MTX or with other conventional-DMARDs seems to be equally effective and safe. However, a CS-sparing effect is only observed with combined ABA.
引用
收藏
页码:299 / 308
页数:10
相关论文
共 50 条
  • [31] Refractory Rheumatoid Arthritis and Associated Interstitial Lung Disease: Could Abatacept be the Answer?
    Ye, Weiyu
    Fifield, Maeve C.
    Ostor, Andrew J. K.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2017, 23 (02) : 125 - 126
  • [32] Window of Opportunity in the Treatment of Rheumatoid Arthritis - Interstitial Lung Disease with Abatacept. National Multicenter Study of 526 Patients
    Serrano-Combarro, Ana
    Atienza-Mateo, Belen
    Paino, Libe Ibarrola
    Casafont-Sole, Ivette
    Loarce, Jesus
    Blanco Madrigal, Juan Maria
    Castaneda, Santos
    Ortega-Castro, Rafaela
    Mena Vazquez, Natalia
    Vegas Revenga, Nuria
    Dominguez Casas, Lucia
    Peralta Gines, Cilia
    Retuerto Guerrero, Miriam
    Perez Albadalejo, Lorena
    Lopez Sanchez, Ruben
    Manzano Canabal, Maria Guadalupe
    Brandy-Garcia, Anahy Maria
    Lopez Viejo, Patricia
    Bonilla, Gema
    Maiz Alonso, Olga
    Carrasco-Cubero, Carmen
    Garijo Bufort, Marta
    Urruticoechea Arana, Ana
    Ordonez, Sergi
    Gonzalez Montagut, Carmen
    Garcia-Valle, Andrea
    Ramon De Dios, Juan
    Martin Lopez, Maria
    Vazquez Rodriguez, Tomas
    Fernandez-Lozano, Delia
    Brana Abascal, Ignacio
    Melero-Gonzalez, Rafael Benito
    Giner, Emilio
    Ruiz-Esquide, Virginia
    Ventin Rodriguez, Clara
    Rodriguez, Marina
    Andujar-Brazal, Pablo
    Fernandez Melon, Julia
    Lopez-Nunez, Lilian M.
    Lamua Riazuelo, Jose Ramon
    Pamies Corts, Anna
    Fernandez Diaz, Carlos
    Loricera, Javier
    Ferrer, Diego
    Blanco-Alonso, Ricardo
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4548 - 4550
  • [33] Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease
    Mena-Vazquez, Natalia
    Rojas-Gimenez, Marta
    Fuego-Varela, Clara
    Garcia-Studer, Aimara
    Perez-Gomez, Nair
    Maria Romero-Barco, Carmen
    Javier Godoy-Navarrete, Francisco
    Manrique-Arija, Sara
    Gandia-Martinez, Myriam
    Calvo-Gutierrez, Jerusalem
    Morales-Garrido, Pilar
    Mourino-Rodriguez, Coral
    Castro-Perez, Patricia
    Anon-Onate, Isabel
    Espildora, Francisco
    Carmen Aguilar-Hurtado, Maria
    Hidalgo Conde, Ana
    Diez de los Rios, Rocio Arnedo
    Cabrera Cesar, Eva
    Redondo-Rodriguez, Rocio
    Luisa Velloso-Feijoo, Maria
    Fernandez-Nebro, Antonio
    BIOMEDICINES, 2022, 10 (07)
  • [34] Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review
    Vicente-Rabaneda, Esther F.
    Atienza-Mateo, Belen
    Blanco, Ricardo
    Cavagna, Lorenzo
    Ancochea, Julio
    Castaneda, Santos
    Gonzalez-Gay, Miguel A.
    AUTOIMMUNITY REVIEWS, 2021, 20 (06)
  • [35] Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients
    Serrano-Combarro, Ana
    Atienza-Mateo, Belen
    Ibarrola-Paino, Libe
    Casafont-Sole, Ivette
    Melero-Gonzalez, Rafael Benito
    Perez Linaza, Alba
    Castaneda, Santos
    Ortega Castro, Rafaela
    Mena Vazquez, Natalia
    Vegas Revenga, Nuria
    Dominguez Casas, Lucia Cristina
    Peralta, Cilia
    Perez-Sandoval, Trinidad
    Perez-Albadalejo, Lorena
    Lopez-Sanchez, Ruben
    Manzano Canabal, Maria Guadalupe
    Brandy-Garcia, Anahy Maria
    Lopez-Viejo, Patricia
    Bonilla, Gema
    Maiz-Alonso, Olga
    Carrasco-Cubero, Carmen
    Garijo Bufort, Marta
    Moreno, Mireia
    Urruticoechea, Ana
    Ordonez-Palau, Sergio
    Gonzalez-Montagut Gomez, Carmen
    Garcia-Valle, Andrea
    Jimenez De Aber, Juan Ramon De Dios
    Lozano, Fernando
    Vazquez-Rodriguez, Tomas
    Martin-Lopez, Maria
    Blanco-Madrigal, Juan Maria
    Fernandez-Lozano, Delia
    Brana Abascal, Ignacio
    Loarce-Martos, Jesus
    Giner-Serret, Emilio
    Ruiz-Esquide, Virginia
    Ventin-Rodriguez, Clara
    Rodriguez-lopez, Marina
    Andujar-Brazal, Pablo
    Fernandez-Melon, Julia
    Maria Lopez, Lilian
    Fernandez-Diaz, Carlos
    Loricera, Javier
    Ferraz Amaro, Ivan
    Ferrer, Diego
    Blanco, Ricardo
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4291 - 4294
  • [36] Interstitial Lung Disease in Elderly Rheumatoid Arthritis Patients
    Riccardo Messina
    Giuliana Guggino
    Alida Benfante
    Nicola Scichilone
    Drugs & Aging, 2020, 37 : 11 - 18
  • [37] Interstitial Lung Disease in Elderly Rheumatoid Arthritis Patients
    Messina, Riccardo
    Guggino, Giuliana
    Benfante, Alida
    Scichilone, Nicola
    DRUGS & AGING, 2020, 37 (01) : 11 - 18
  • [38] INTERSTITIAL LUNG DISEASE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
    Kur-Zalewska, J.
    Raczkiewicz, A.
    Bujakowska, O.
    Juszkiewicz, A.
    Tlustochowicz, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 913 - 914
  • [39] Radiological evaluation of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept or JAK inhibitors for 1 year
    Mochizuki, Takeshi
    Yano, Koichiro
    Ikari, Katsunori
    Okazaki, Ken
    RESPIRATORY INVESTIGATION, 2023, 61 (03) : 359 - 363
  • [40] Cohort study of serological biomarkers for interstitial lung disease in patients with rheumatoid arthritis
    Colmenares, V
    Hedman, A.
    Hesslow, A.
    Wahlin, B.
    Sodergren, A.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2024, 53 (06) : 386 - 395